




cancers



an Open Access Journal by MDPI

The Biological Diversity and Therapeutic Implications of Medulloblastoma Metastases and Recurrence

Guest Editor:

Dr. Laura Donovan

UCL Great Ormond Street
Institute of Child Health, London
WC1N 1EH, UK

Deadline for manuscript
submissions:
closed (25 January 2024)

Message from the Guest Editor

Medulloblastoma is the most common malignant childhood brain tumour. For patients with recurrent medulloblastomas following current standard-of-care protocols, the disease is almost universally fatal (<10% survival rate), and therefore, represent some of the most significant unmet clinical challenges in paediatric oncology. Medulloblastoma subgroups remain unchanged at recurrence; however, the divergent clonal selection from primary disease to metastases and recurrence is complex. Little is understood about the molecular drivers required for medulloblastoma metastasis and survival within the leptomeningeal space. Given the lack of human data at the level of metastasis and recurrence, the refinement of preclinical models may improve our understanding of resistance mechanisms, and suggest new treatment strategies for subsequent clinical trials.

This Special Issue, entitled ‘The Biological Diversity and Therapeutic Implications of Medulloblastoma Metastases and Recurrence’, aims to highlight the complexities of medulloblastoma through primary, metastatic, and recurrent disease progression, as well as prioritizing strategies to implement in future clinical trials.



mdpi.com/si/152447

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI